Several other analysts have also commented on EVT. Oddo Bhf set a €22.00 ($25.58) price objective on Evotec and gave the stock a buy rating in a report on Tuesday, June 12th. Deutsche Bank set a €21.00 ($24.42) price objective on Evotec and gave the stock a buy rating in a report on Monday, August 13th.
Shares of EVT opened at €21.30 ($24.77) on Friday. Evotec has a one year low of €7.91 ($9.20) and a one year high of €22.50 ($26.16).
Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services, as well as absorption, distribution, metabolism, excretion, and toxicity services.
Featured Article: Price to Earnings Ratio (PE) Basics
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.